• 1
    Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs K. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther 2012; 35: 63446.
  • 2
    Matsumura T, Kato T, Sugiyama N, et al. 25-hydroxyvitamin D(3) suppresses hepatitis C virus production. Hepatology 2012; 56: 12319.
  • 3
    Petta S, Camma C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 115867.
  • 4
    Falleti E, Bitetto D, Fabris C, et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 2012; 56: 164150.
  • 5
    Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 88793.
  • 6
    Bitetto D, Fattovich G, Fabris C, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 111826.
  • 7
    Kitson MT, Dore GJ, George J, et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 2013; 58: 46772.
  • 8
    Stauber RE, Scherzer T, Putz-Bankuti J, et al. Baseline vitamin D levels do not influence SVR in patients with chronic HCV genotype 1 or 4 infection undergoing perinterferon/ribavirin treatment. J Hepatol 2011; 54: S468.
  • 9
    Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2–3 naive patients. World J Gastroenterol 2012; 18: 8005.
  • 10
    Bitetto D, Fabris C, Fornasiere E, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24: 4350.
  • 11
    Almerighi C, Franceschelli A, Francioso S, et al. High dose vitamin D supplementation in genotype 1 chronic hepatitis C patients with advanced fibrosis/compensated cirrhosis non responders to previous standard therapy: Results of the HEP-D3 Study. Hepatology 2011; 54: 857858A.
  • 12
    Baur K, Mertens JC, Schmitt J, et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int 2012; 32: 63543.
  • 13
    Corey KE, Zheng H, Mendez-Navarro J, et al. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS ONE 2012; 7: e27144.
  • 14
    Weintraub SJ, Fleckenstein JF, Marion TN, Madey MA, Mahmoudi TM, Schechtman KB. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr 2012; 96: 102531.
  • 15
    Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 538791.
  • 16
    Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19: 738.
  • 17
    Sonderman JS, Munro HM, Blot WJ, Signorello LB. Reproducibility of serum 25-hydroxyvitamin d and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol 2012; 176: 61521.
  • 18
    Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 2004; 37: 86774.
  • 19
    Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, D.C.: National Academy Press, 2010. (Ref Type: Report).
  • 20
    Subar AF, Thompson FE, Kipnis V, et al. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol 2001; 154: 108999.
  • 21
    Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101: 54755.
    Direct Link:
  • 22
    Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 188796.
  • 23
    Morali G, Maor Y, Klar R, et al. Fibrotest-Actitest: the biochemical marker of liver fibrosis–the Israeli experience. Isr Med Assoc J 2007; 9: 58891.
  • 24
    Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE 2012; 7: e30325.
  • 25
    Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 17703.
  • 26
    Jovanovich A, Chonchol M, Cheung AK, et al. Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 6407.
  • 27
    Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010; 20: 135260.
  • 28
    Lange CM, Bibert S, Kutalik Z, et al. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS ONE 2012; 7: e40159.
  • 29
    Barchetta I, Carotti S, Labbadia G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012; 56: 21807.
  • 30
    Ho AS, Cheng CC, Lee SC, et al. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010; 17: 58.